Navigation Links
Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:2/8/2011

CAMBRIDGE, Mass., Feb. 8, 2011 /PRNewswire/ -- Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

Vascugel, a novel endothelial cell-based therapy and Pervasis' lead development program, aims to regulate the body's healing response following surgical interventions to create vascular access points which are necessary for ESRD patients undergoing hemodialysis, reducing the need for repeat surgical interventions and improving overall patient outcomes.

FDA established Fast Track to facilitate the development and accelerate the pre-market review of treatments for serious and life-threatening conditions, so that these products can reach approval more rapidly. To receive Fast Track designation, a product must address a serious unmet medical condition, and be supported by strong results from pre-clinical or clinical testing demonstrating the product potential.

Vascugel has demonstrated clinical proof of concept in two Phase 2 clinical trials involving patients with ESRD who require a permanent arteriovenous (AV) access for hemodialysis. In these trials, Vascugel exhibited an excellent safety profile and encouraging efficacy trends were observed, including improved duration of patency (or unimpeded blood flow) and a delay in time to first intervention as compared to placebo.

"The fact that these very sick patients must endure serious complications and repeat surgical procedures so that they can continue undergoing hemodialysis represents a significant unmet medical need—one that Vascugel is uniquely able to address," stated Frederic Chereau, president and CEO of Pervasis. "Fast Track designation from the FDA further validates Vascugel's potential as a safe and effective therapy for patients with end stage renal disease, and will help accelerate the
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
2. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
3. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
4. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
5. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
6. China Medicine Corporation Receives Manufacturing License for rADTZ
7. Johnson & Johnson Receives Approval from European Commission
8. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
9. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
10. China Sky One Medical Receives Medical Industry Awards
11. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; ... a provisional patent application with the United States ... treatment of Epidermolysis Bullosa Simplex (EBS) using novel ... Dr. Sazzad Hossain , ... excited to file our first patent covering the ...
(Date:5/25/2015)... Chain Drugstore Ltd. (NYSE: NPD ) ("Nepstar" or the ... on the number of directly operated stores, today announced ... 31, 2015. Financial Highlights , Same ... quarter of 2014 , Revenue increased by 11.9% ... the first quarter of 2014 , Net loss ...
(Date:5/22/2015)... , May 22 2015 /CNW/ - The Taskforce representing ... very appreciative of all the hard work that the Minister ... past six months. This program recognizes the needs of the ... at least $75,000 a year, tax free, with annual adjustments ... be eligible for annual payments of $100,000 based on the ...
Breaking Medicine Technology:InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 2InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS) 3China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports First Quarter 2015 Financial Results 11
... MOUNTAIN VIEW, Calif., Feb. 28, 2011 VIVUS, ... to the development and commercialization of novel therapeutic products, today ... and year ended December 31, 2010. ... development program, we successfully completed the two-year SEQUEL study, an ...
... The staffs of Chiltern International Limited (Chiltern), a global ... 25 year mark of their successful collaboration in Drug ... have worked together using a validated and regulatory accepted ... assessment of drug phototoxicity. The history of this collaboration ...
Cached Medicine Technology:VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 2VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 3VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 4VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 5VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 6VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 7Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 2Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 3
(Date:5/26/2015)... (PRWEB) May 26, 2015 Allprovide, the ... of fresh, all-natural dog foods are now available in ... in Atlanta and The Good Old Dog Company in ... where they’ve recently opened a state-of-the-art, climate controlled facility. ... farmers’ markets and all of the food is triple-tested ...
(Date:5/26/2015)... 26, 2015 Mr. Larry Westenberg is ... in Neuro-Linguistic Programming, or NLP. Mr. Westenberg is ... Resolution Therapy® or RRT®. While many people have ... applied it to specific areas, Mr. Westenberg has been ... over 20 years. He works with people suffering ...
(Date:5/26/2015)... 2015 Based on numerous suggestions put ... a comprehensive upgrade of its purchasing page and processing, ... thank users for their feedback and support of the ... trial transcription service promotion. , This promotion will ... June 9 this year. During this period, AnyTranscription users ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Scientists at ... a way to help advanced mesothelioma patients benefit from ... just posted an article on the new research. ... in the departments of thoracic surgery and pulmonology theorized ... suppress an immune system attack, immunotherapy drugs might work ...
(Date:5/26/2015)... May 26, 2015 On June 4, ... complimentary live online broadcast at 6:00pm PST/9:00 pm EST. ... Trivedi Master™ Alice Branton welcomes the public to attend ... night of profound knowledge, transformation and enlightenment. The ... and no previous knowledge, experience or other prerequisites are ...
Breaking Medicine News(10 mins):Health News:Allprovide, the All-Natural Pet Food, Available At Georgia Retailers 2Health News:Enjoy AnyTranscription’s First-class Audio/Video Transcription Service for Just $0.01 2Health News:Enjoy AnyTranscription’s First-class Audio/Video Transcription Service for Just $0.01 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 2Health News:The Human Wellness Company Trivedi Master Wellness™ Opens a Complimentary Transformational Community Call to the Public on June 4, 2015 3
... , WHITE PLAINS, N.Y., July 14 A new ... - alerting them to a patient,s increased risk for birth defects ... agreement with a $1.2 million grant from the Health Resources and ... The National Coalition for Health Professional Education in Genetics ...
... ... and senior partner at the Pederson Immigration Law Group, P.C. is slated to be ... , ... (PRWEB) July 14, 2009 - The Pederson Immigration Law Group, P.C., (PILG) announced that ...
... , , , ... leading provider of electronic medical records systems, electronic prescribing and advanced ... on June 24(th), 2009. meridianEMR users will now be able to ... in communities throughout all 50 states and Washington, D.C. , ...
... 14, 2009 News media covering chemical sciences, small ... Chemical Society (ACS) Small & Medium Business Webinar on ... and entrepreneurs. Scheduled for Thursday, July ... will feature Kenneth Polk, who joined ACS in October ...
... KANSAS CITY, Mo., July 14 We have all heard this warning: ... Do we first notice the hair, the eyes, or the clothing? ... smile is the first feature we notice about someone. Smiling is also ... we should all be interested in making sure we are taking care of ...
... 14 To help the general public better understand the ... on Skin Cancer Prevention has issued a position statement on ... recommends that vitamin D be obtained from a combination of ... ultraviolet (UV) radiation. , , ...
Cached Medicine News:Health News:New HHS HRSA Grant Will Fund Development of an Electronic Genetic and Family History Record for Doctors' Offices 2Health News:New HHS HRSA Grant Will Fund Development of an Electronic Genetic and Family History Record for Doctors' Offices 3Health News:Pederson Immigration Law Group Attorneys Featured in 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series 2Health News:Pederson Immigration Law Group Attorneys Featured in 14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series 3Health News:meridianEMR Completes Surescripts(R) Certification 2Health News:meridianEMR Completes Surescripts(R) Certification 3Health News:Want to attract the opposite sex? It's in the Smile. 2Health News:National Council on Skin Cancer Prevention Encourages Americans to Obtain Vitamin D Through Diet and Supplements 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: